MedTrace Logo

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

NCT05443984 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-08-27

No results posted yet for this study

Summary

To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis

Conditions

  • Erosive Esophagitis

Interventions

DRUG

JP-1366 20mg

1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)

DRUG

Esomeprazole 40mg

1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)

Sponsors & Collaborators

  • Onconic Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-17
Primary Completion
2023-01-05
Completion
2023-01-05

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05443984 on ClinicalTrials.gov